3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
5
Phase 1/2
4
Phase NA
3
Phase 3
2
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
22
Other hematologic neoplasm
18
Plasma cell
11
Thoracic
3
Gastrointestinal
3
Breast
3
Tumor-Agnostic
2
Genitourinary
2
Myeloid
1
Head & Neck
1
Gynecologic
1
Conditions
Lymphoma, Extranodal NK-T-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Interventions
nilotinib
12
Imatinib Mesylate
11
Dasatinib
3
ruxolitinib
2
posaconazole
2
fludarabine
2
bosutinib
2
asciminib
2
Cyclophosphamide
2
Busulfan
2
zanubrutinib
1
trametinib
1
pegaspargase
1
flumatinib
1
fludarabine phosphate
1
eltrombopag
1
dabrafenib
1
avapritinib
1
Thiotepa
1
Rituximab
1
Radiotherapy
1
Phlebotomy
1
Peripheral Blood Stem Cell Transplantation
1
Panobinostat
1
Micafungin
1
Interferons
1
Idarubicin
1
Hydroxyurea
1
Growth Hormone
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Dexamethasone
×
Myeloid
×
Clear all
NCT04999878
2021-08-11
RUE-DDGP
Zhengzhou University
Phase 4
Unknown
30 enrolled